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Abstract  
Background: Randomized trials may be designed to provide evidence more strongly related to 
efficacy or effectiveness of an intervention. When systematic reviews are used to inform clinical 
or policy decisions, it is important to know the efficacy-effectiveness nature of the included 
trials.  
Objective: To develop a tool to characterize randomized trials included in a systematic review on 
an efficacy-effectiveness continuum.  
Methods: We extracted rating domains and descriptors from existing tools, and used a modified 
Delphi procedure to condense the domains and develop a new tool. The feasibility and inter-rater 
reliability of the tool was tested on trials from 4 systematic reviews.   
Results: The RITES (Rating of Included Trials on the Efficacy-effectiveness Spectrum) tool rates 
clinical trials on a 5-point Likert scale in four domains: (1) participant characteristics, (2) trial 
setting, (3) flexibility of interventions, and (4) clinical relevance of interventions. When RITES 
was piloted on trials from 3 reviews by unaffiliated raters, ratings were variable (Intraclass 
Correlation Coefficient 0.25-0.66 for the four domains), but when RITES was used on 1 review 
by the review authors with expertise on the topic the ratings were consistent (ICCs >0.80.   
Conclusion: RITES may help to characterize the efficacy-effectiveness nature of trials included 
in systematic reviews.  
 
Running title: RITES: A new tool for rating trials in systematic reviews 
Keywords: Comparative Effectiveness Research; Systematic reviews; Randomized controlled 
trials; Pragmatic trial; Explanatory trial; Effectiveness; Efficacy; Applicability 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4 
Introduction 
 
Randomized controlled trials (RCTs) are often characterized as designed with either a more 
explanatory or a more pragmatic approach [1]. RCTs taking an explanatory design approach 
determine whether an intervention produces the expected result under ideal research 
circumstances and are intended to provide evidence on the efficacy of an intervention: Does the 
treatment work in an optimal setting under standardized conditions? RCTs taking a pragmatic 
design approach measure the degree of beneficial effect under “real world” clinical conditions 
and are intended to provide evidence on the effectiveness of an intervention: Does the treatment 
work in the usual care setting under realistic conditions? The design of RCTs is generally not 
either fully explanatory or completely pragmatic but rather placed along a continuum between 
the two, where this continuum may vary for different aspects of the trial design and conduct. The 
Pragmatic-Explanatory Continuum Indicatory Summary (PRECIS, later modified to PRECIS-2) 
is a tool which was developed to help designers of RCTs make decisions regarding 10 trial 
domains in accordance with explanatory versus pragmatic design goals [2, 3]. Similarly, the 
evidence provided by a trial may be situated along an efficacy-effectiveness continuum. We use 
the terms explanatory and pragmatic when we address the trials and their design, and we use the 
terms efficacy and effectiveness when we address the evidence provided by a RCT. 
 
To understand whether a RCT is potentially useful to inform clinical decision making in usual 
care (i.e., the setting and type of care routinely received by patients with the condition) it is 
important to know if the study provides evidence about the efficacy or the effectiveness of an 
intervention. Evidence about efficacy may be obtained from a carefully controlled experimental 
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comparison (e.g., between an active drug and a placebo, or in a highly selected (homogenous) 
group of participants). Evidence about effectiveness may be obtained from comparisons between 
clinically relevant interventions carried out in settings and participants that are representative of 
usual care. In the first scenario the trials provide evidence about efficacy, which may provide 
important information on the specific effects of an intervention when deployed under optimally 
controlled conditions. In the second scenario, the trials may be susceptible to some forms of bias 
(e.g. information bias, due to difficulty in blinding the comparison between two clinically 
relevant interventions), but they provide evidence to inform decision-making in usual care. 
Understanding whether the trials included in a systematic review describe the efficacy or the 
effectiveness of a treatment will help readers, including clinicians and health policy decision 
makers, understand whether the review provides information that is more relevant to the specific 
actions of the intervention under assessment circumstances or information that may be more 
directly applicable to real-world implementation. 
 
Researchers have previously used PRECIS (or adaptations of PRECIS) to retrospectively 
characterize ongoing or completed trials along the efficacy-effectiveness continuum and thus 
describe the nature of the reported evidence [4-9]. However, PRECIS and PRECIS-2 were 
developed to inform choices during the trial design phase, rather than to assess the characteristics 
of trial evidence retrospectively from the publication of the trial. They assume detailed 
familiarity with available design options at the time that the trial is being designed, and this 
information may not be available in the report of a completed trial. In addition, PRECIS-2 
assesses nine trial domains which may limit the practicality for use on the often substantial 
number of trials included in a systematic review. A tool for use with systematic reviews should 
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be short and focused on the essential elements of the efficacy-effectiveness spectrum that are 
likely to be described in a trial report. We are not aware of any short, practical tools that have 
been systematically designed and validated specifically for characterizing completed trials along 
an efficacy-effectiveness continuum for retrospective use in systematic reviews [4]. Our aim was 
therefore to identify all available tools for evaluating the efficacy-effectiveness of trials, to 
extract the concepts from these tools, and to develop a short and feasible tool that informs 
decision-makers reading systematic reviews about whether the evidence provided by the 
included trials is information about the efficacy or the effectiveness of an intervention. 
 
Methods 
 
Searching for existing tools 
 
We began by searching the literature for existing tools used to measure the pragmatic-
explanatory or efficacy-effectiveness characteristics of RCTs. One author (LSW) searched 
PubMed and Web of Science in March 2014 for tools or adaptations of tools used to classify 
trials along this pragmatic-explanatory or efficacy-effectiveness continuum (Search strategy in 
Box 1).  
 
Developing the tool 
 
We used a modified Delphi procedure that included 2 rounds working with two expert groups. A 
core expert group (the14 authors of this publication), consisting of scientists affiliated with our 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7 
Center and leading experts in comparative effectiveness research or in methods for conducting or 
reporting randomized trials and systematic reviews, developed the tool. Our Delphi expert panel 
was a larger group that included stakeholders in comparative effectiveness research, trial 
methodology, and reporting methods, who were invited to take part in the Delphi procedure and 
provide feedback. We collected names of these experts from lists of authors of publications using 
tools to measure the pragmatic-explanatory or effectiveness-efficacy characteristics of trials, 
authors of CONSORT (Consolidated Standards of Reporting Trials) statements or extensions, 
authors of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta Analyses) 
statements, and members of the Practihc (Pragmatic Randomized Controlled Trials in 
HealthCare) group, the Cochrane Applicability and Recommendations Methods Group, and the 
Cochrane Complementary Medicine Field.  
 
Delphi round 1: We extracted information from tools and adaptations of tools found in the 
literature and constructed a table of the domains and criteria (Table 1) for which a RCT could be 
characterized as having a more explanatory-efficacy or a more pragmatic-effectiveness 
orientation, together with descriptors of maximum explanatory-efficacy or maximum pragmatic-
effectiveness characteristics for each criterion. We consulted with the core expert group to ensure 
that all relevant domains were included in this table. We then e-mailed a group of researchers we 
had identified as appropriate participants for a Delphi expert panel. We sent them the table of 
domains and criteria, and invited them to reply to an online survey on the perceived importance 
(on a scale of 1-10 with 1=not at all important and 10=extremely important) and ease of rating 
(on a scale of 1-10 with 1=not at all easy and 10=extremely easy) for each domain. We also 
asked the panel to rate the ease of using (on a scale of 1-10 with 1=not at all easy and 
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10=extremely easy) a rating scheme based on three categories (efficacy, between efficacy and 
effectiveness, effectiveness), or on a 5, 10 or 20-point numerical rating scale.  
  
We circulated the feedback from the first Delphi round to our core expert group, and held a 
teleconference and had written exchanges to decide upon the most relevant domains, revised the 
domain descriptors, and selected the rating scheme for an initial draft of the tool.  
 
In the second round of the Delphi procedure we repeated the e-mailed invitation and this time 
presented the initial draft of the tool and asked the panel to rate the clarity of an introductory 
explanation of the tool concepts on a scale of 1-10 with 1=not at all clear and 10=extremely 
clear. We also requested respondents to rate how confident they would be in rating each domain 
from a completed publication on a scale of 1-10 with 1=not at all confident and 10=extremely 
confident. Finally, we asked whether transforming the summarized results of the 5-point rating 
scale into percentages would be a clear way to present the results. Respondents were asked to 
rate the clarity of such a transformation on a scale of 1-10 with 1=not at all clear and 
10=extremely clear. We brought the results of the second online survey to our core expert group 
during a second teleconference and series of written exchanges, and finalized the tool. 
 
Pilot testing 
 
We tested the feasibility and inter-rater reliability of the tool by applying it to four Cochrane 
reviews. We selected the trials included in a Cochrane review on artichoke leaf extract for 
treating hypercholesterolaemia (3 trials) [10], a Cochrane review on yoga for epilepsy (2 trials) 
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[11], and a Cochrane review being prepared for acupuncture in the treatment of hip osteoarthritis 
(5 trials) (unpublished update of a previous review [12]). Our goal was to test the tool on a range 
of different populations, interventions, and comparators, and we therefore used multiple small 
reviews from our list of Cochrane reviews related to complementary medicine. We asked 12 
researchers, 7 of whom (JB, LB, CD, ST, DvdW, LSW, CW) were members of the core expert 
group in the tool development. The remaining five had experience in systematic reviews but 
were ‘naïve’ to the tool, to independently carry out ratings of each trial such that 10 raters rated 
each domain for each trial. We also wanted to test the tool with authors of an ongoing systematic 
review, and for this purpose we asked the two authors of an update to a Cochrane review on 
acupuncture for migraine to rate each of 8 trials in the updated review [13]. One of the authors 
(KL) was involved in the tool development, but the other author was ‘naïve’. All raters were 
requested to give comments on anything that was difficult or unclear about the ratings process. 
We then observed the range of ratings and calculated intraclass correlation coefficients [14] 
using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina) to determine inter-rater 
reliability for each domain of the tool for each trial. The results were discussed in a conference 
call with the core expert group and followed up by written exchanges to finalize the descriptors 
of the tool domains. 
 
Developing visual representation of the ratings 
 
We subsequently developed a visual representation of the ratings of effectiveness/efficacy of 
individual trials within a systematic review. This visual representation was presented to the core 
experts in a conference call and discussed in written exchanges until consensus was reached.  
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Results 
 
Results of searches 
The searches retrieved 1,880 citations after de-duplication. They were screened by two authors 
(LSW, CW) for descriptions of tools or revisions of tools for measuring RCTs on a pragmatic-
explanatory or efficacy-effectiveness continuum. One new citation describing the planned 
revision of PRECIS (PRECIS-2) [15] was identified, and several citations mentioning that 
PRECIS was used to assess ongoing or completed trials. Aside from the citation describing the 
plans for PRECIS-2, we did not identify any other publications describing the existence of tools 
or modifications of tools that we had not already identified during the planning for this project. 
The tools or measures that we had already identified were: Gartlehner et al.’s simple tool to 
distinguish between efficacy and effectiveness studies [16], PRECIS [2], and four modifications 
or adapted uses of PRECIS, including Koppenaal et al.’s adaptation of PRECIS for systematic 
reviews [5], Tosh et al.’s Pragmascope [8], Selby et al.’s enhancement of PRECIS [7], and 
Glasgow et al.’s application of PRECIS to effectiveness trials [6]. None of these instruments was 
developed to rate published trials retrospectively. We included these tools together with the 
description of the development of PRECIS-2 [15] and later the final report for PRECIS-2 [3] as 
resources for the initial identification of efficacy-effectiveness criteria for the tool. 
 
Results of the Delphi rounds  
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There were 72 respondents (20.45% response rate) out of 352 persons invited to the first Delphi 
round. Respondents classified each of the criteria in Table 1 as at least moderately important for 
rating the efficacy-effectiveness of an RCT, with medians ranging from 7-9 on a scale of 1-10 
where higher numbers reflect greater importance. However, the confidence with which 
individual criteria could be rated was lower for some items, ranging from 5-9 on a scale of 1-10 
where higher numbers reflect greater confidence. Respondents also noted that some criteria were 
already assessed and reported elsewhere in a systematic review (e.g., blinding of participants and 
personnel), some criteria would likely require special clinical or other expertise to rate, and 
several criteria could probably be combined. With regard to the preferred rating scheme, the 
respondents reported that rating of each aspect of trial design from 1 (efficacy) to 5 
(effectiveness) would be easier than rating each aspect from 1 to 10, from 1 to 20, or in three 
categories (efficacy, between efficacy and effectiveness, effectiveness). (See Table 2 for the 
results of the first Delphi round). 
 
There were 69 respondents (19.62% response rate) out of 352 persons invited to the second 
Delphi round. The respondents found the proposed introductory text to the draft tool to be clear 
(mean (sd) of 7.6 (2.3) and median of 8 on a scale of 1-10 where higher numbers reflect greater 
clarity) and were fairly confident that each of the four items on the draft tool could be rated on 
the basis of a published report of an the RCT at issue (see the description of each domain of the 
final RITES tool, below, for details). The display or summarized results using percentages was 
rated as not very clear (mean (sd) of 6.5 (2.7) and median of 7 on a scale of 1-10 where higher 
numbers reflect greater clarity).  Based on the feedback from the second Delphi round, no 
modifications were made to the proposed introductory text for the final tool. However, after 
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discussion, the core experts made some wording changes to the four domains of the draft tool, 
and added notes defining the meaning of ‘usual care’ and explaining how participants were to be 
judged.  
 
Description of the final RITES Tool 
 
The final RITES tool contains 4 domains, which are each rated on a 5-point scale from a strong 
emphasis on efficacy to a strong emphasis on effectiveness (Table 3). The domains are: 
participants’ characteristics, trial setting, flexibility of intervention(s), and clinical relevance of 
experimental and comparison intervention(s).  
 
Participants’ characteristics 
The domain of participants’ characteristics corresponds closely to the concept of eligibility in 
PRECIS and PRECIS-2, although it considers additional factors beyond eligibility criteria, such 
as whether the participants were actually similar in age, severity of illness, and comorbidities to 
those participants who would be candidates for the intervention in usual care [2, 3]. In the second 
Delphi round, the confidence in assessing this domain from a study report was a mean (sd) of 7.3 
(1.9) and a median of 8. 
 
Trial setting 
The domain of trial setting blends elements of setting and practitioner expertise in PRECIS and 
organization in PRECIS-2 [2, 3]. In the second survey, the confidence in assessing this domain 
from a study report was a mean (sd) of 7.4 (2.0) and a median of 8. 
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Flexibility of intervention(s) 
The domain of flexibility of intervention(s) corresponds closely to the combined PRECIS 
concepts of flexibility in practitioner adherence to study protocol, flexibility in delivery of the 
intervention, and flexibility in participant adherence to the intervention [2, 15]. In the second 
survey, the confidence in assessing this domain from a study report was a mean (sd) of 7.7 (1.9) 
and a median of 8. 
 
Clinical relevance of experimental and comparison intervention(s) 
The domain of clinical relevance of experimental and comparison intervention(s) draws from the 
PRECIS domain of the flexibility of the comparison intervention [2], Gartlehner et al.’s focus on 
intervention duration [16], and the IOM concept of clinical and policymaker relevance [17]. In 
the second survey, the confidence in assessing this domain from a study report was a mean (sd) 
of 7.1 (2.2) and a median of 8. 
 
Rating scale 
The evidence from the RCT is rated for each domain along a 5-point Likert Scale ranging from 
1= strong emphasis on efficacy to 5 = strong emphasis on effectiveness. When information on 
this domain is not available, the rating NA may be used. Because the second Delphi round 
indicated that transforming the ratings into percentages of efficacy or effectiveness was not very 
clear, the core experts group decided that this transformation was not appropriate. 
 
Results of piloting 
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The results of RITES piloting are presented in the online Appendix. For five of the ten RCTs 
from three Cochrane reviews on a range of topics, one or two domains within individual RCTs 
were rated as reflecting more emphasis on efficacy (e.g., mean (sd) of 1.4 (0.7) and range 1 to 3) 
or effectiveness (e.g., mean (sd) of 4.3 (0.7) and range 3 to 5). However, most of the ratings were 
inconsistent, with a large amount of variability between ratings and many cases in which the 
ratings spanned the entire spectrum of possible ratings on a dimension (i.e., 1 to 5).  The 
intraclass correlation coefficients were low to moderate for each of the four tool dimensions, 
ranging from a low of 0.23 for trial setting to a high of 0.45 for clinical relevance.  When three 
outlying raters with ratings s 3 standard deviations from the mean were removed from the 
dataset, most correlations were substantially higher, ranging from 0.25 for flexibility of 
interventions to 0.66 for clinical relevance. There was no obvious pattern of differences between 
the more expert and the ‘naïve’ raters. In some cases raters stated that it was difficult to come up 
with a rating on a domain when one aspect of the domain tended to reflect a more efficacy 
orientation and other aspects of the domain tended to reflect a more effectiveness orientation. 
However, raters primarily commented on difficulties in ratings due to lack of available 
information in the study report, or due to lack of clinical expertise in the medical condition or 
knowledge of the interventions.  
 
In contrast, when two review authors rated trials included in their updated Cochrane review of 
acupuncture for migraine, the ratings were highly consistent. Although one author was involved 
in development of this tool (KL) and one author was ‘naïve’ to the tool, the two raters frequently 
agreed on ratings and the ratings were never more than one point apart (e.g., 2 and 3, or 4 and 5), 
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although in some instances one of the raters felt that there was insufficient information in the 
published report to make a rating (Appendix). Five of the RCTs were rated as showing a greater 
emphasis on efficacy across all domains, two of the RCTs were rated as showing a greater 
emphasis on effectiveness across all domains, and one RCT was rated as possessing a stronger 
emphasis on efficacy in two domains, and as slightly more on the efficacy side in the third 
domain and slightly more on the effectiveness side in the fourth domain. The  intraclass 
correlation coefficients were 0.8 or higher for each domain. 
 
Results of visual representation 
 
The visual representation (Figure 1) displays the averages of the ratings by the two raters for 
each domain for each trial in the acupuncture for migraine review. The ratings do not take into 
account sample size of the trials, or weighting of the RCTs within one or more meta-analyses. 
Only RCTs for which both authors rated information as available on a domain are included in the 
visual for that domain. In the case of the this review, the rated studies showed a lot of 
heterogeneity across the spectrum. The visual clearly shows that 2 of the studies (numbers 7 and 
8) tended to be more on the effectiveness side in all domains, while the other studies for which 
there was available information tended to be more on the efficacy side.  
 
Discussion 
 
We developed the RITES tool to provide authors and readers of systematic reviews with a rating 
scale to assess whether the included RCTs provide predominantly information about the efficacy 
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or effectiveness of an intervention. We have taken multiple criteria for effectiveness and efficacy 
from PRECIS and other sources, and consolidated the criteria into four key domains in which 
randomized trials may display information that has a greater emphasis on effectiveness or on 
efficacy. Unlike PRECIS, which was developed to assist in planning trials, RITES was 
systematically designed to be suitable for assessing completed trials from a study report. Our 
next steps will include development of processes for incorporating RITES into the conduct and 
reporting of a systematic review. 
 
The ratings of effectiveness and efficacy are not intended to reflect trial quality. Pragmatic trials 
(which produce effectiveness information) and explanatory trials (which produce efficacy 
information) can each be of higher or lower quality and consequently differ in their risk of bias, 
depending upon how they are designed and carried out. Ratings of risk of bias are expected to be 
carried out separately for trials within a review, and although these ratings may in some cases be 
associated with aspects of efficacy or effectiveness such that it is easier for an explanatory study 
that tests efficacy to earn a low risk of bias score, we do not seek to establish or explore any such 
relationships here. However, it may be promising to include an examination of this relationship 
in future studies in order to get an impression of the construct validity of RITES.        
 
A possible limitation of this study was the low response rate (approximately 20%) to our 
invitations to participate on the Delphi panels. We invited a wide range of participants to the 
Delphi panel, in order to receive input from stakeholders in comparative effectiveness research, 
systematic reviews, trial methodology, and research reporting. It is possible that most of the 
people we invited did not have sufficient interest or expertise in the intersections of effectiveness 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 17
research, systematic reviews, and research methods, to consider participating. We did not collect 
information on the characteristics of the participants in the first Delphi panel. However, we asked 
respondents to the second Delphi panel for their expertise with systematic reviews and their prior 
knowledge of PRECIS; 46/69 (67%) responded that they were regularly involved in producing 
systematic reviews and 39/69 (57%) that they were familiar with PRECIS, of whom 19/39 (49%) 
had used PRECIS, indicating that we were successful in soliciting input from a range of users 
and producers of research.  
 
The variability of the results from our pilot suggests that RITES will perform best when it is used 
as intended, by authors rating the trials included in their systematic review.  Our piloting on eight 
trials of acupuncture for migraine has shown that the tool may be successfully used in systematic 
reviews of RCTs to identify domains in which information is more about efficacy or more about 
effectiveness. 
 
A common difficulty in carrying out the pilot ratings of the ten trials on a range of topics was the 
lack of background knowledge of the raters regarding the patient population, the setting, and the 
intervention. Several raters commented during piloting that they had insufficient clinical 
knowledge to carry out the RITES rating with confidence. This problem of uncertainty was not 
seen in the pilot ratings of the eight acupuncture for migraine trials, probably because review 
authors are likely to have more familiarity with the clinical population and the relevant treatment 
options and delivery characteristics. However, we should consider whether there might be a need 
to develop guidance for review authors who have limited clinical expertise, and incorporate this 
guidance in training resources developed for raters. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18
 
Even if raters are familiar with the clinical condition, they may still encounter difficulties when 
rating RCTs that were carried out in very different environments, such as older trials or trials 
carried out in other countries. For example, if the usual care setting for treatment is primary care, 
but in previous decades or particular regions of the world the usual care setting is instead 
secondary or tertiary care, the raters must be able to recognize this. Furthermore, it is unclear 
how to apply the assessments of efficacy or effectiveness from these ‘other’ environments to the 
clinical setting for which the review needs to be informative. This situation was not encountered 
in our pilot ratings, but piloting with a range of trials carried out in different eras and different 
geographical regions will likely present opportunities to develop methods to deal with these 
situations. 
 
Finally, work needs to be done with the RITES tool to identify and develop ways in which the 
ratings may be of practical use to users of the systematic review. A visual representation of the 
status of individual trials across domains, similar to the one we developed for the acupuncture for 
migraine ratings, would likely be part of this development. An indication of the importance and 
interpretation of measurement differences in ratings (e.g., of one unit in the domain rating) 
would also be important. This tool, which is greatly indebted to previous work elucidating the 
concepts of the pragmatic-explanatory approaches for clinical trial design [2, 3], is an 
opportunity to clarify the importance and relevance of effectiveness and efficacy approaches 
within the context of the systematic review. We welcome suggestions and collaboration in the 
further refinement of the tool and its application. 
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Box 1. Search strategies  
PubMed search strategy: 
 ("Randomized Controlled Trials as Topic" OR "Clinical Trials as Topic") AND (tool[tiab] OR spectrum[tiab] 
OR continuum[tiab]) AND (pragmatic[tiab] OR explanatory[tiab] OR efficacy[tiab] OR effectiveness[tiab]) 
Web of Science searches: 
All citations of the main publications on PRECIS [2, 18] or the explanatory publication for the CONSORT 
extension to pragmatic trials [19]. 
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Table 1. Table of domains previously used to characterize trials along the effectiveness-efficacy continuum 
Domain 
 
Criterion* Descriptor for trial with maximum 
effectiveness orientation 
Descriptor for trial with maximum efficacy 
orientation 
Participants 
 
 
Eligibility [15] 
 
How similar are the participants to those who 
would receive the intervention if it was part of 
usual care?  
There are many exclusions (e.g. those who 
don’t comply, respond to treatment, or are not 
at high risk for primary outcome, are children 
or elderly), or the trial uses many selection 
tests not used in usual care.  
Recruitment [15] Recruitment is through usual appointments or 
clinic  
Recruitment is through targeted information 
letters, advertising in newspapers, radio plus 
incentives and other routes that would not be 
used in usual care.  
Setting and 
Interventions 
 
 
Setting [15] The setting is identical to usual care.  The setting is only a single center or only 
specialized trial or academic centers.  
Organization [15] The resources, provider expertise and the 
organization of care delivery in the 
intervention arm are identical to usual care.  
The trial increases staff levels, gives additional 
training, requires more than the usual 
experience or certification, or certification and 
increase resources.  
Comparison 
intervention 
practitioner 
expertise [2] 
The comparison intervention typically is 
applied by the full range of practitioners, and 
in the full range of clinical interest, regardless 
of their expertise, with only ordinary attention 
to their training, experience, and performance.  
In an explanatory trial, practitioner expertise in 
applying the comparison intervention(s) is 
standardized so as to maximize the chances of 
detecting whatever comparative benefits the 
experimental intervention might have.  
Flexibility 
(delivery) [15] 
 
Flexibility in the intervention is identical to 
that in usual care.  
Intervention delivery is less flexible than usual 
care. There is a strict protocol, monitoring and 
measures to improve compliance, with specific 
advice on allowed co-interventions and 
complications.  
Flexibility of the 
comparison 
intervention [2] 
In a pragmatic trial, ‘‘Usual practice’’ or the 
best available alternative management 
strategy, offering practitioners considerable 
leeway in deciding how to apply it.  
In an explanatory trial, restricted flexibility of 
the comparison intervention.  
Other Design 
Aspects 
Comparison 
relevance to a 
The comparison has the objective of directly 
informing a specific clinical decision from the 
The comparison is not relevant to a specific 
patient or policymaker decision. 
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specific patient or 
policymaker 
decision [17] 
patient perspective or a health policy decision 
from the population perspective.  
Clinical relevance 
of experimental 
and comparison 
intervention [17] 
Both the experimental and comparison 
intervention have the potential to be ‘best 
practice’.  
One or both of the experimental and 
comparison interventions is not a clinically 
relevant treatment (e.g., placebo, sub-clinical 
doses). 
Study duration 
[16] 
The duration of the study should mimic a 
minimum length of treatment in a clinical 
setting to allow the assessment of health 
outcomes  
The duration of the study is shorter than the 
minimum length of treatment in a clinical 
setting. 
Blinding of 
participants and 
personnel to the 
intervention [20, 
21] 
Clinician and patient biases are not necessarily 
viewed as detrimental but accepted as part of 
physicians' and patients' responses to treatment 
and included in the overall assessment.  
Participants and investigators blinded where 
possible to minimize bias  
Follow-up [15] No more than the follow-up expected in usual 
care.  
Compared to usual care, more frequent or 
longer visits, unscheduled visits triggered by 
primary outcome event or intervening event, 
and more extensive data collection.  
Primary outcome 
[15] 
The primary outcome is of obvious importance 
to participants.  
The primary outcome uses a surrogate, 
physiological outcome, central adjudication or 
uses assessment expertise that is not available 
in usual care, or the outcome is measured at an 
earlier time than in usual care.  
Flexibility 
(adherence) [15] 
There is no more than usual encouragement to 
adhere to the intervention.  
Exclusion based on adherence and measures to 
improve adherence if found wanting.  
Practitioner 
adherence to study 
protocol [2] 
There is unobtrusive (or no) measurement of 
practitioner adherence and no special 
strategies to maintain or improve it are used.  
There is close monitoring of how well the 
participating clinicians and centers are 
adhering to even the minute details in the trial 
protocol and ‘‘manual of procedures.’’  
Primary analysis 
[15] 
The most pragmatic approach is to use 
intention to treat with all available data.  
The most explanatory analysis is one that 
excludes ineligible post-randomization 
participants and includes only those following 
the treatment protocol.  
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*Each criterion is associated with one or more references to a rating tool or other source for the concept.  
Analysis at the 
population and 
subgroup level 
[16, 17] 
Subgroup analyses to discern the effects in 
subjects with common clinical characteristics. 
Study is adequately powered to detect 
minimally important differences in important 
outcomes for important subgroups.  
No preplanned subgroup analyses. 
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Table 2 Results from the Delphi survey round 1 (n= 72 responders) 
Domain Criterion Importance* Rating confidence* 
  n responses/ 
n missing 
Mean (sd) Median 
(range) 
n responses/ 
n missing 
Mean (sd) Median 
(range) 
Participants 
 
Eligibility 70/2 8.8 (1.9) 9 (1-10) 69/3 6.8 (1.9) 7 (3-10) 
Recruitment 69/3 6.4 (2.4) 7 (1-10) 69/3 6.5 (2.4) 7 (1-10) 
Setting and 
Interventions 
 
 
  
  
  
Setting 69/3 7.4 (2.1) 8 (2-10) 69/3 7.2 (2.0) 8 (2-10) 
Organization 68/4 7.4 (2.2) 8 (2-10) 69/3 6.0 (2.1) 6 (2-10) 
Comparison intervention 
practitioner expertise 
69/3 7.9 (1.8) 8 (2-10) 69/3 6.0 (2.2) 6 (1-10) 
Flexibility (delivery) 69/3 8.3 (1.9) 9 (1-10) 69/3 6.7 (2.3) 7 (1-10) 
Flexibility of the 
comparison intervention 
68/4 7.8 (2.1) 8 (2-10) 68/4 6.2 (2.2) 6 (1-10) 
Other Design 
Aspects 
 
Comparison relevance to 
a specific patient or 
policymaker decision 
67/5 6.9 (2.3) 7 (2-10) 67/5 6.0 (2.3) 5 (2-10) 
Clinical relevance of 
experimental and 
comparison intervention 
68/4 8.1 (2.3) 9 (1-10) 68/4 7.5 (2.0) 8 (1-10) 
Study duration 69/3 7.8 (2.2) 8 (1-10) 70/2 7.7 (2.2) 8 (1-10) 
Blinding of participants 
and personnel to the 
intervention 
70/2 7.6 (2.4) 8 (1-10) 70/2 7.5 (2.4) 8 (1-10) 
Follow-up 70/2 7.3 (2.2) 8 (1-10) 69/3 7.3 (2.2) 8 (1-10) 
Primary outcome 69/3 8.0 (2.5) 9 (1-10) 69/3 8.0 (2.0) 9 (1-10) 
Flexibility (adherence) 70/2 7.9 (2.2) 8 (1-10) 69/3 6.6 (2.1) 7 (1-10) 
Practitioner adherence to 
study protocol 
70/2 7.3 (2.2) 8 (1-10) 70/2 5.5 (2.6) 6 (1-10) 
Primary analysis 70/2 8.1 (2.4) 9 (1-10) 70/2 7.6 (2.2) 8 (1-10) 
Analysis at the 
population and subgroup 
level 
70/2 6.5 (2.9) 7 (1-10) 69/3 6.6 (2.5) 7 (1-10) 
* Ratings made on a scale from 1-10, where 1 is least importance or confidence, and 10 is maximum importance or confidence. 
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Table 3: RITES (Rating Included Trials on the Efficacy-Effectiveness Spectrum) tool introductory text, criteria, and rating scale 
 
Trials are often characterized as designed with either a more explanatory or a more pragmatic approach. Trials 
taking an explanatory design approach determine whether an intervention produces the expected result under 
ideal circumstances and are intended to provide evidence on the efficacy of an intervention. Trials taking a 
pragmatic design approach measure the degree of beneficial effect under “real world” clinical settings and are 
intended to provide evidence on the effectiveness of an intervention. A trial design is often not completely on 
either the explanatory or pragmatic side but rather along a continuum between the two and the placement of the 
trial along this continuum may vary for different aspects of the trial design and conduct. Similarly the evidence 
provided by a trial is placed within an efficacy-effectiveness continuum. We use the terms explanatory and 
pragmatic when we address the trials and their design. We use the terms efficacy and effectiveness when we 
address the evidence provided by a trial. 
 
Criteria Descriptor for efficacy orientation Descriptor for maximum effectiveness 
orientation 
1. Participants 
characteristics
* 
 
 
 
The participants are a homogeneous 
population and are markedly different 
from those seen in usual care. 
Participants may be deliberately 
selected to comply with treatment, 
respond to treatment, or demonstrate the 
efficacy of the experimental 
intervention (e.g., be at high risk for the 
primary outcome). There may be other 
exclusions that would not be seen in 
usual care** (e.g. exclusion of 
participants with comorbidities). 
The participants are representative of 
the population who would receive the 
experimental intervention if it was part 
of usual care**. They are similar in age, 
severity of illness, and comorbidities to 
those patients who would be candidates 
for the intervention in a usual care** 
setting. They reflect diversity along 
parameters that could impact adherence. 
 
2. Trial setting  
 
 
The setting is selected to maximize the 
ability to carry out the trial and identify 
an intervention effect if there is one. 
The setting may be more specialized 
than the setting in which the 
experimental intervention would be 
delivered in usual care (e.g. a single 
The overall setting of the trial is similar 
to usual care** and includes diverse 
sub-settings common in usual care** 
for this intervention (e.g. primary care, 
specialized care). 
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center, specialized clinics or only 
specialized trial or academic centers or 
only providers with high levels of 
experience). 
 
3. Flexibility 
of 
intervention(s)  
 
 
Experimental and comparison 
intervention delivery is less flexible 
than usual care. There is a strict 
protocol, monitoring, and measures to 
improve intervention adherence. There 
is specific advice on prohibited co-
interventions. [15](15)(14)(16) 
Flexibility in the experimental and 
comparison interventions is identical to 
that in usual care**.  Co-interventions 
may be permitted. 
 
4. Clinical 
relevance of 
experimental 
and 
comparison 
intervention(s) 
One or both of the experimental and 
comparison interventions is not a 
clinically relevant or best current 
treatment (e.g., placebo, no-treatment 
control, sub-clinical doses), or study 
duration is shorter than the minimum 
length of treatment in usual care**. 
Both the experimental and comparison 
intervention have the potential to be 
‘best practice’/best current treatment. 
The duration of the interventions is 
similar to the minimum length of 
treatment in usual care**. 
 
 
*Participants included in the study should be judged according to whether they are representative of the general population of those with the condition of interest who would 
receive usual care in the geographic area in which the trial is carried out.  
**Usual care describes the type of care routinely received by patients in the geographic area in which the trial is carried out. The care provided can vary by patient characteristics 
(e.g. age, sex, education), the setting (inpatient/outpatient, primary care/specialized care) in which the patient is seen, individual providers and insurance plans. 
 
Based upon a 5-point Likert Scale the evidence deriving from each domain should be rated: 
1 = strong emphasis on efficacy 
2 = rather strong emphasis on efficacy 
3 = balanced emphasis on both efficacy and effectiveness 
4 = rather strong emphasis on effectiveness 
5 = strong emphasis on effectiveness 
NA = information not available
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Figure 1. Visual presentation of the efficacy-effectiveness of trials within a systematic review 
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What is new 
 
 
Key findings 
• We developed Rating of Included Trials on the Efficacy-Effectiveness Spectrum 
(RITES), a tool to rate the evidence from trials included in systematic reviews 
along a continuum between maximum efficacy and maximum effectiveness.  
 
What this adds to what was known 
• Trials are often characterized as designed to produce information more related to 
effectiveness or to efficacy. Decision-makers reading systematic reviews may 
consider it important to understand whether the evidence provided by the included 
trials is information about the efficacy or the effectiveness of an intervention.  
• RITES is the first tool systematically designed specifically for characterizing 
evidence from completed trials along an efficacy-effectiveness continuum for 
retrospective use in systematic reviews. 
 
What is the implication, what should change now 
• We are developing additional guidance on how to carry out ratings. We are also 
working on clarifying how the ratings can be of practical use to readers of 
systematic reviews.  
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Appendix - Results from Piloting of RITES 
 
 
A. Ten trials from 3 different reviews, each trial rated by 10 raters 
 
1. Participants  
 
Trial Mean SD min max Number of 
raters providing 
ratings 
Number of 
raters unable 
to rate 
Artichoke leaf extract for hypercholesterolaemia 
Trial 1 2.7 0.9 1 4 10 0 
Trial 2 3.0 0.8 2 4 10 0 
Trial 3 1.9 1.5 1 5 9 1 
SUMMARY 2.5      
Yoga for epilepsy 
Trial 4  3.7 1.0 2 5 10 0 
Trial 5 3.6 1.1 2 5 10 0 
SUMMARY 3.6      
Acupuncture for hip osteoarthritis 
Trial 6 2.2 0.6 1 3 10 0 
Trial 7 4.0 1.2 1 5 10 0 
Trial 8 3.9 0.9 2 5 10 0 
Trial 9 3.3 1.1 2 5 10 0 
Trial 10 4.1 0.9 2 5 10 0 
SUMMARY MEAN 3.5      
 
 
2. Trial Setting  
 
Trial Mean SD min max Number of 
raters providing 
ratings 
Number of 
raters unable 
to rate 
Artichoke leaf extract for hypercholesterolaemia 
Trial 1 2.7 1.4 1 5 10 0 
Trial 2 2.9 0.7 2 4 10 0 
Trial 3 1.7 1.2 1 3 4 6 
SUMMARY 2.4      
Yoga for epilepsy 
Trial 4  3.3 1.6 1 5 10 0 
Trial 5 2.4 0.7 2 4 10 0 
SUMMARY 2.9      
Acupuncture for hip osteoarthritis 
Trial 6 1.8 1.2 1 4 8 2 
Trial 7 3.3 1.4 1 5 10 0 
Trial 8 3.3 0.5 3 4 10 0 
Trial 9 3.1 1.0 3 4 9 1 
Trial 10 4.4 0.5 4 5 10 0 
SUMMARY MEAN 3.5      
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3. Flexibility of Intervention  
 
Trial Mean SD min max Number of 
raters providing 
ratings 
Number of 
raters unable 
to rate 
Artichoke leaf extract for hypercholesterolaemia 
Trial 1 2.1 1.4 1 5 10 0 
Trial 2 2.0 0.8 1 3 10 0 
Trial 3 1.6 0.8 1 3 8 2 
SUMMARY 1.9      
Yoga for epilepsy 
Trial 4  2.9 0.8 2 4 9 1 
Trial 5 2.5 0.9 1 4 9 1 
SUMMARY 2.7      
Acupuncture for hip osteoarthritis 
Trial 6 2.3 0.8 1 4 10 0 
Trial 7 2.8 0.8 2 4 10 0 
Trial 8 3.2 1.1 2 5 10 0 
Trial 9 2.6 1.3 1 4 10 0 
Trial 10 4.3 0.7 3 5 10 0 
SUMMARY MEAN 3.0      
 
 
4. Clinical Relevance 
 
Trial Mean SD min max Number of 
raters providing 
ratings 
Number of 
raters unable 
to rate 
Artichoke leaf extract for hypercholesterolaemia 
Trial 1 1.8 1.0 1 4 10 0 
Trial 2 1.4 0.7 1 3 10 0 
Trial 3 1.8 1.4 1 5 10 0 
SUMMARY 1.7      
Yoga for epilepsy 
Trial 4  4.2 1.0 2 5 10 0 
Trial 5 2.7 1.2 1 5 10 0 
SUMMARY 3.4      
Acupuncture for hip osteoarthritis 
Trial 6 2.2 1.3 1 5 10 0 
Trial 7 4.0 0.7 3 5 10 0 
Trial 8 4.0 1.1 2 5 10 0 
Trial 9 2.3 1.7 1 5 10 0 
Trial 10 4.3 0.7 3 5 10 0 
SUMMARY MEAN 3.4      
 
 
Correlation coefficient according to Sprout and Fleiss 
RITES Inter-rater-correlation 
Participants 0.25823 
Trial Setting 0.23498 
Flexibility of Intervention 0.26437 
Clinical Relevance 0.44532 
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B. Eight trials from 1 review, each trial rated by 2 authors of the review  
 
1. Participants  
 
Trial Mean SD min max Number of 
raters 
providing 
ratings 
Number of 
raters 
unable to 
rate 
Acupuncture for migraine   
Trial 1 -- -- 2 2 1 1 
Trial 2 2 0 2 2 2 0 
Trial 3 1.5 0.7 1 2 2 0 
Trial 4 2.5 0.7 2 3 2 0 
Trial 5 -- -- 2 2 1 1 
Trial 6 1.5 0.7 1 2 2 0 
Trial 7 5 0 5 5 2 0 
Trial 8 4 0 4 4 2 0 
SUMMARY MEAN 2.75      
 
2. Trial Setting  
 
Trial Mean SD min max Number of 
raters 
providing 
ratings 
Number of 
raters 
unable to 
rate 
Acupuncture for migraine   
Trial 1 -- -- 1 1 1 1 
Trial 2 2 0 2 2 2 0 
Trial 3 2 0 2 2 2 0 
Trial 4 -- -- 2 2 1 1 
Trial 5 1.5 0.7 1 2 2 0 
Trial 6 1 0 1 1 2 0 
Trial 7 5 0 5 5 2 0 
Trial 8 4.5 0.7 4 5 2 0 
SUMMARY MEAN 2.66      
 
3. Flexibility of Intervention  
 
Trial Mean SD min max Number of 
raters 
providing 
ratings 
Number of 
raters 
unable to 
rate 
Acupuncture for migraine   
Trial 1 -- -- 2 2 1 1 
Trial 2 1.5 0.7 1 2 2 0 
Trial 3 1 0 1 1 2 0 
Trial 4 1.5 0.7 1 2 2 0 
Trial 5 1 0 1 1 2 0 
Trial 6 1 0 1 1 2 0 
Trial 7 4 0 4 4 2 0 
Trial 8 5 0 5 5 2 0 
SUMMARY MEAN 2.14      
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4. Clinical Relevance 
 
Trial Mean SD min max Number of 
raters 
providing 
ratings 
Number of 
raters 
unable to 
rate 
Acupuncture for migraine   
Trial 1 -- -- 1 1 1 1 
Trial 2 1.5 0.7 1 2 2 0 
Trial 3 1.5 0.7 1 2 2 0 
Trial 4 3.5 0.7 3 4 2 0 
Trial 5 1.5 0.7 1 2 2 0 
Trial 6 1.5 0.7 1 2 2 0 
Trial 7 4.5 0.7 4 5 2 0 
Trial 8 5 0 5 5 2 0 
SUMMARY MEAN 2.71      
 
 
 
Correlation coefficient according to Sprout and Fleiss 
RITES Inter-rater-correlation 
Participants 0.86437 
Trial Setting 0.92162 
Flexibility of Intervention 0.94225 
Clinical Relevance 0.85143 
 
 
